Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News In Brief From Elcelyx, Medivir, Repligen

Executive Summary

Elcelyx spins out new company to advance weight-loss supplement while it focuses on delayed-release metformin for type 2 diabetes. Also, Medivir announces promising data for a combination of HCV drugs in patients with advanced fibrosis or cirrhosis of the liver, while Repligen has earned its first milestone under a collaboration in spinal muscular atrophy with Pfizer.

You may also be interested in...



Isis Moves SMA Drug Forward As Market Interest For The Rare Disease Expands

Spinal muscular atrophy is a rare disease that affects a small patient population of children. Isis is ready to move its compound into mid-stage testing after positive Phase I results, but the biotech isn’t the only company exploring the field.

Shionogi's Oral COVID Drug Set For Global Access Through MPP

Agreement with UN-affiliated body set to expand global availability in lower income countries of Japanese firm’s protease inhibitor, which has faced approval road bumps at home but now looks set to move forward on positive new Phase III data.

Medicare CED Update Targets Study ‘Efficiency,’ But May Not Ease Data Collection Burden

It's not clear that the proposed revisions and additions to the Centers for Medicare and Medicaid Services’ existing coverage with evidence development study design requirements would address what some experts view as a program failure – the fact that sponsors of the vast majority of technologies subject to CED have not generated the data CMS is looking for. 

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS055585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel